acute myocardial infarction

El éxito de la angioplastia sobre las CTO por reestenosis disminuye la mortalidad cardíaca

Restenosis Does Not Seem as Benign as We Thought

Elective, uncomplicated repeat revascularization after stent restenosis is associated with higher mortality rates according to a new meta-analysis that will be published soon in J Am Coll Cardiol Intrv. Historically, interventional cardiologists have seen target lesion revascularization (TLR) as a procedure that “unjustly” increased combined events in clinical studies and our own databases, thus representing<a href="https://solaci.org/en/2018/05/16/restenosis-does-not-seem-as-benign-as-we-thought/" title="Read more" >...</a>

El éxito en las CTO reduce la isquemia residual local y a distancia

Hybrid Revascularization or Conventional Surgery: History Is Still Being Written

Hybrid revascularization seems to achieve results similar to those of conventional myocardial revascularization surgery at 5 years, although studies published so far do not seem to be enough for a definitive answer. This new work, soon to be published in J Am Coll Cardiol Intv, has had promising results in selected patients with multivessel disease; however,<a href="https://solaci.org/en/2018/05/07/hybrid-revascularization-or-conventional-surgery-history-is-still-being-written/" title="Read more" >...</a>

La cirugía parece superior a la angioplastia en pacientes jóvenes

TAVR with Prior MRS: A New Challenge

The benefits of transcatheter aortic valve replacement (TAVR) for high-risk, prohibitive-risk (class I) or intermediate-risk (class IIa) patients have already been proven, but there is a growing population of patients with a history of myocardial revascularization surgery (MRS) who experience severe aortic stenosis. Decision-making in these cases is anything but simple, mainly due to the presence of<a href="https://solaci.org/en/2018/05/02/tavr-with-prior-mrs-a-new-challenge/" title="Read more" >...</a>

Estenosis-aórtica-severa2-compressor

We Should Consider Mitral Stenosis Before TAVR

The association between aortic stenosis and some degree of mitral stenosis (MS) is around 10% (depending on the series), and it is related with negative outcomes. In high-risk and inoperable patients who underwent TAVR, that association and its significance have not been studied yet. &nbsp; The study analyzed data from the Society of Thoracic Surgeons/American<a href="https://solaci.org/en/2018/04/21/we-should-consider-mitral-stenosis-before-tavr/" title="Read more" >...</a>

ACC 2018 | Risk of MI in Non-Cardiac Surgeries

One in five patients presenting perioperative MI during non-cardiac surgery should be readmitted within 30 days after surgery, and one in seven dies within the same period, according to the new study presented at ACC 2018 scientific sessions and simultaneously published in Circulation. These infarctions could be considered a iatrogenic complication, given the obvious lack of proper<a href="https://solaci.org/en/2018/04/09/acc-2018-risk-of-mi-in-non-cardiac-surgeries/" title="Read more" >...</a>

ACC 2018 | SMART-DATE: 6 Month DAPT Results Suboptimal in ACS

This study compared 6 vs 12 or more months of dual antiplatelet therapy (DAPT) in patients undergoing acute coronary syndrome (ACS) receiving contemporary DES, and it did not find differences in combined endpoint. However, looking at primary endpoint components separately, there were more infarctions in patients with a short DAPT scheme that we cannot ignore. Prolonging antiaggregation<a href="https://solaci.org/en/2018/04/08/acc-2018-smart-date-6-month-dapt-results-suboptimal-in-acs/" title="Read more" >...</a>

¿Cuál es la mejor antiagregación en la angioplastia primaria a 12 meses?

What Is the Best Antiplatelet Therapy in Primary Angioplasty at 12 Months?

Both prasugrel and ticagrelor showed superiority in terms of efficacy, reducing the number of major cardiovascular events at the expense of increased bleeding. This is an affordable cost, and the net clinical benefit supports these new antiplatelet therapies. The one-year follow-up of the PRAGUE-18 study focused on a comparison of efficacy and safety between prasugrel<a href="https://solaci.org/en/2018/03/07/what-is-the-best-antiplatelet-therapy-in-primary-angioplasty-at-12-months/" title="Read more" >...</a>

Sorpresivo pronóstico para los infartos con coronarias normales

Surprising Prognosis for Normal ACS

St elevation acute coronary syndromes&nbsp;are typically caused by thrombotic obstruction of a coronary artery due to ruptured atherosclerosis plaque. However, there is a significant number of patients with similar clinical presentations but no evidence of obstructive&nbsp;coronary artery disease (CAD). Read also:&nbsp;CTO in patients with acute myocardial infarction increases long term mortality. In general, patients without<a href="https://solaci.org/en/2018/03/01/surprising-prognosis-for-normal-acs/" title="Read more" >...</a>

Statin Pre-Treatment for the Prevention of Peri-Procedural Events in Carotid Artery Stenting

What is the effect of statins on amputations, and survival in peripheral vascular disease?

The prevalence of peripheral arterial disease is between 15% and 20% of patients older than 65 years and its severity is greatly underestimated. In fact, annual mortality is higher in patients with peripheral arterial disease (8.2%) than in those after acute myocardial infarction (6.3%). Despite the above, medical advice and efforts to modify risk factors<a href="https://solaci.org/en/2018/02/26/what-is-the-effect-of-statins-on-amputations-and-survival-in-peripheral-vascular-disease/" title="Read more" >...</a>

El estudio CULPRIT-SHOCK finalmente se publica en el NEJM y llega para cambiar las guías

The CULPRIT-SHOCK Study Is Finally Published in NEJM and It Is Bound to Change Guidelines

During SOLACI’s coverage of the TCT 2017 Congress in Denver, Colorado, we already mentioned some of the outcomes of this study that has arrived to revolutionize clinical practice, given the differences between its results and those of the classic SHOCK trial, which has marked for almost 20&nbsp;years the treatment strategy for patients with infarction complicated<a href="https://solaci.org/en/2018/02/09/the-culprit-shock-study-is-finally-published-in-nejm-and-it-is-bound-to-change-guidelines/" title="Read more" >...</a>

Top